Taysha Gene Therapies Up Nearly 39%, on Pace for Largest Percent Increase Since August 2023 -- Data Talk

Dow Jones11-13

Taysha Gene Therapies, Inc. (TSHA) is currently at $2.26, up $0.64 or 38.96%

 

--Would be highest close since Sept. 13, 2024, when it closed at $2.29

--On pace for largest percent increase since Aug. 29, 2023, when it rose 42.02%

--Currently up five consecutive days; up 78.35% over this period

--Longest winning streak since Feb. 22, 2024, when it rose for five straight trading days

--Best five day stretch since the five days ending Aug. 18, 2023, when it rose 159.81%

--Up 34.02% month-to-date

--Up 27.97% year-to-date; on pace for best year on record (Based on available data back to Sept. 24, 2020)

--Down 92.87% from its all-time closing high of $31.75 on Jan. 20, 2021

--Up 70.3% from 52 weeks ago (Nov. 14, 2023), when it closed at $1.33

--Down 45.68% from its 52-week closing high of $4.17 on June 13, 2024

--Up 78.35% from its 52-week closing low of $1.27 on Nov. 5, 2024

--Traded as high as $2.30; highest intraday level since Sept. 16, 2024, when it hit $2.31

--Up 41.1% at today's intraday high; largest intraday percent increase since March 20, 2024, when it rose as much as 41.16%

 

All data as of 1:48:42 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 12, 2024 13:53 ET (18:53 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment